Skip to main content
SpringerLink
Log in

Risk factors for high-dose methotrexate-induced nephrotoxicity

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

High-dose methotrexate (MTX) is widely used for the treatment of hematological malignancies. Despite the application of routine supportive care measures, such as intensive fluid hydration and urine alkalinization, nephrotoxicity is still a problem. The present study aimed to evaluate the risk factors for MTX-induced nephrotoxicity. We retrospectively reviewed 88 patients who received a regimen consisting of high-dose MTX (1000 mg/m2) and cytosine arabinoside between 2006 and 2018. Nephrotoxicity (≥ grade 2) was observed in 11 patients. Nephrotoxicity was observed only in patients with a high MTX concentration. Other than the MTX concentration, the serum uric acid level and urine pH at day 1 were associated with nephrotoxicity. A multivariate analysis revealed that urine pH was an independent risk factor for MTX-induced nephrotoxicity. Urine pH < 7.0 at day 1 was a significant risk factor for nephrotoxicity (odds ratio, 8.05; 95% confidence interval 1.95–33.3) and was also a predictor of delayed MTX elimination at 72 h after injection. Among pre-treatment factors, a low serum calcium level predicted urine pH < 7.0 at day 1. In conclusion, the present study suggests that low urine pH at day 1 is an independent risk factor for MTX-induced nephrotoxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Deborah AT, Stefan F, Susan O, Carlos BR, Jorge C, Guillermo GM, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006;106:1569–80.

    Article  Google Scholar 

  2. Sand TE, Jacobsen S. Effect of urine pH and flow on renal clearance of methotrexate. Eur J Clin Pharmacol. 1981;19:453–6.

    Article  CAS  Google Scholar 

  3. Skarby T, Jonsson P, Hjorth L, Behrentz M, Bjork O, Forestier E, et al. High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL). Cancer Chemother Pharmacol. 2003;51:311–20.

    Article  CAS  Google Scholar 

  4. Jori M, Kenneth RC, Sara B, Weijian L, Nancy LB, Nina DWJ. High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis. Leuk Lymphoma. 2014;55:1345–9.

    Article  Google Scholar 

  5. Jacobs SA, Stoller RG, Chabner B, David GJ. 7- hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate. J Clin Invest. 1976;57:534–8.

    Article  CAS  Google Scholar 

  6. Mikkelsen TS, Mamoudou AD, Tuckuviene R, Wehner PS, Schroeder H. Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study. Pediatr Blood Cancer. 2014;61:297–301.

    Article  Google Scholar 

  7. Jonathan S, Helena E, Robert S. Acetazolamide for alkalinisation of urine in patients receiving high-dose methotrexate. Cancer Chemother Pharmacol. 1991;28:150–1.

    Article  Google Scholar 

  8. Yoshinobu K. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.

    Article  Google Scholar 

  9. Relling MV, Fairclough D, Ayers D, Crom WR, Rodman JH, Pui CH, et al. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol. 1994;12:1667–72.

    Article  CAS  Google Scholar 

  10. Thode J, Fogh-Andersen N, Wimberley PD, Sorensen AM, Andersen OS. Relation between pH and ionized calcium in vitro and in vivo in man. Scand J Clin Lab Invest. 1983;165:79–82.

    Article  CAS  Google Scholar 

  11. Pedersen KO. Binding of calcium to serum albumin, II: effect of pH via competitive hydrogen and calcium ion binding to the imidazole groups of albumin. Scand J Clin Lab Invest. 1972;29:75–83.

    Article  CAS  Google Scholar 

  12. Craig BL, Jorge BC. Calcium in chronic kidney disease: myths and realities. Clin J Am Soc Nephrol. 2010;5:S1–2.

    Article  Google Scholar 

  13. Remer T, Manz F. Potential renal acid load of foods and its influence on urine pH. J Am Diet Assoc. 1995;95:791–7.

    Article  CAS  Google Scholar 

  14. Michaud DS, Troiano RP, Subar AF, Runswick S, Bingham S, Kipnis V, et al. Comparison of estimated renal net acid excretion from dietary intake and body size with urine pH. J Am Diet Assoc. 2003;103:1001–7.

    Article  Google Scholar 

  15. Cameron JM, Elaine MW, Fredric LC, John A, Kristin JB, Benjamin K. Mechanisms for falling urine pH with age in stone formers. Am J Physiol Renal Physiol. 2019;317:F65–72.

    Article  Google Scholar 

  16. Brandon JO, Shahab B, Jennifer K, Muna C, Vincent GB, Canales B. Age, body mass index, and gender predict 24-hour urine parameters in recurrent idiopathic calcium oxalate stone formers. J Endourol. 2017;31:1335–41.

    Article  Google Scholar 

  17. Nicola A, Manisha C, Alberto VC Jr, Orson WM, Khashayar S. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int. 2004;65:386–92.

    Article  Google Scholar 

  18. Naoko N, Michiaki F, Muhei T, Hitoshi T, Saeko I, Masahiro Y, et al. Low urine pH is a predictor of chronic kidney disease. Kidney Blood Press Res. 2012;35:77–81.

    Article  Google Scholar 

  19. Laura BR, John CP, Colton S, Wenjian Y, Yiping F, Naomi JW, et al. Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood. 2013;121:898–904.

    Article  Google Scholar 

  20. Evelien GEH, Marije JK, Sita HV, Melanie MH, Uta F, Bart HWS, et al. Analysis of drug metabolizing gene panel in osteosarcoma patients identifies association between variants in SULT1E1, CYP2B6 and CYP4F8 and methotrexate levels and toxicities. Front Pharmacol. 2020;11:1–9.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan

    Shinichiro Kawaguchi, Shin-ichiro Fujiwara, Rui Murahashi, Hirotomo Nakashima, Sae Matsuoka, Takashi Ikeda, Yumiko Toda, Shoko Ito, Tetsuaki Ban, Takashi Nagayama, Kento Umino, Daisuke Minakata, Hirofumi Nakano, Ryoko Yamasaki, Masahiro Ashizawa, Chihiro Yamamoto, Kaoru Hatano, Kazuya Sato, Iekuni Oh, Ken Ohmine & Yoshinobu Kanda

  2. Division of Cell Transplantation and Transfusion, Jichi Medical University Hospital, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan

    Shin-ichiro Fujiwara

Authors
  1. Shinichiro Kawaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shin-ichiro Fujiwara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rui Murahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hirotomo Nakashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sae Matsuoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takashi Ikeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yumiko Toda
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shoko Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tetsuaki Ban
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Takashi Nagayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Kento Umino
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Daisuke Minakata
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Hirofumi Nakano
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Ryoko Yamasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Masahiro Ashizawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Chihiro Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Kaoru Hatano
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Kazuya Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Iekuni Oh
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Ken Ohmine
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Yoshinobu Kanda
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SK designed the study and collected the data. SK, SI, and YK analyzed the data and wrote the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Yoshinobu Kanda.

Ethics declarations

Conflict of interest

The authors declare no conflicts of interest.

Ethical approval

For this retrospective study, formal informed consents is not required. This retrospective study was approved by Jichi Medical University Clinical Research Ethics Committee.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kawaguchi, S., Fujiwara, Si., Murahashi, R. et al. Risk factors for high-dose methotrexate-induced nephrotoxicity. Int J Hematol 114, 79–84 (2021). https://doi.org/10.1007/s12185-021-03132-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-021-03132-8

Keywords

Search

Navigation